百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BGNE 百济神州

休市中 12-20 15:59:59 EST

176.50

+1.78

+1.02%

盘后177.10

+0.60+0.34%

17:23 EST

最高179.25	最低175.80	成交量36.83万
今开176.29	昨收174.72	日振幅1.97%
总市值187.52亿	流通市值112.71亿	总股本1.06亿
成交额6,521万	换手率0.58%	流通股本6,386万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":176.5,"timestamp":1734728399999,"preClose":174.72,"halted":0,"volume":368336,"hourTrading":{"tag":"盘后","latestPrice":177.1,"preClose":176.5,"latestTime":"17:23 EST","volume":45232,"amount":7983522.32,"timestamp":1734733397830},"delay":0,"floatShares":63856225,"shares":106246194,"eps":-8.186614,"marketStatus":"休市中","marketStatusCode":7,"change":1.78,"latestTime":"12-20 15:59:59 EST","open":176.29,"high":179.25,"low":175.8,"amount":65212444.92288,"amplitude":0.019746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.186614,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":1,"adjPreClose":174.72,"adrRate":13,"preHourTrading":{"tag":"盘前","latestPrice":175.99,"preClose":174.72,"latestTime":"08:05 EST","volume":38,"amount":6640.4297,"timestamp":1734699902954},"postHourTrading":{"tag":"盘后","latestPrice":177.1,"preClose":176.5,"latestTime":"17:23 EST","volume":45232,"amount":7983522.32,"timestamp":1734733397830},"volumeRatio":0.8523008001419023,"impliedVol":0.4329,"impliedVolPercentile":0.4405},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2493260769","title":"肿瘤药竞赛，上了新高度","url":"https://stock-news.laohu8.com/highlight/detail?id=2493260769","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493260769?lang=zh_cn&edition=full","pubTime":"2024-12-22 08:43","pubTimestamp":1734828238,"startTime":"0","endTime":"0","summary":"过去几年，强生在骨髓瘤领域，给市场上了一课。目前，强生富有层次感的交接棒正在形成，相关产品2023年收入也已突破百亿美元大关。这或许也预示了，肿瘤药的竞赛，在不知不觉中已经上了新高度。在这一逻辑下，肿瘤药物的竞争高度不断上行。这也是头部肿瘤药企进行广泛而精准布局的核心。一方面，泽布替尼表现强势，是全球获批适应症最广泛且在CLL新患市场取得领导地位的新一代BTK抑制剂，支","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/247504","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BGNE","BK4097","LU0307460666.USD","LU0588546209.SGD","BK4211","BK4548","LU1969619763.USD","BK1583","BK4504","BK4588","BK1161","06160","PFS","BK4526","BK4585","BK1500","BK1588","BK4195","BK4505","BK4139","OS","LU2328871848.SGD","BK4535"],"gpt_icon":0},{"id":"2492288114","title":"百济神州ADC肿瘤新药在中国获批临床！","url":"https://stock-news.laohu8.com/highlight/detail?id=2492288114","media":"康可药研","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492288114?lang=zh_cn&edition=full","pubTime":"2024-12-20 23:42","pubTimestamp":1734709332,"startTime":"0","endTime":"0","summary":"今日，中国国家药监局药品审评中心官网公示，百济神州申报的1类新药注射用BG-C137获批临床，拟开发用于晚期实体瘤患者。根据CDE官网查询，本次为该产品首次在中国获批临床。注射用BG-C137是由百济神州开发的一款FGFR2b ADC药物。根据百济神州公开资料，该公司2024年已经有超过10个新分子实体进入临床。尤其是11月以来，该公司多款新药陆续获批临床，包括BG-T187、BG-C477、BGB-58067。此外，新型EGFR降解剂BG-60366片临床试验申请已经获得CDE受理，也有望在2024年进入临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220234322a1fe47c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220234322a1fe47c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1588","LU0307460666.USD","688235","06160","BGNE","LU0588546209.SGD","LU1969619763.USD","BK1500","LU2328871848.SGD"],"gpt_icon":0},{"id":"2492448617","title":"百济神州收盘下跌0.22%，最新市净率9.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2492448617","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492448617?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:50","pubTimestamp":1734699055,"startTime":"0","endTime":"0","summary":"12月20日，百济神州今日收盘161.22元，下跌0.22%，最新市净率9.23。截至2024年三季报，共有146家机构持仓百济神州，其中基金142家、其他4家，合计持股数5264.34万股，持股市值95.00亿元。百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。最新一期业绩显示，2024年三季报，公司实现营业收入191.36亿元，同比48.63%；净利润-3686694000.0元，同比4.94%，销售毛利率83.94%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205455ab8726a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205455ab8726a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","BGNE","06160"],"gpt_icon":0},{"id":"2492465192","title":"机构重申对百济神州(06160)“买入”评级，看好其强大的肿瘤药物研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2492465192","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492465192?lang=zh_cn&edition=full","pubTime":"2024-12-20 13:36","pubTimestamp":1734673014,"startTime":"0","endTime":"0","summary":"近期，百济神州(06160)举办投资者电话会议，介绍在美国血液学会(ASH)和圣安东尼奥乳腺癌研讨会(SABCS)上的重要数据展示。随后，TD Cowen重申百济神州“买入”评级，维持260.00美元的目标价，这与众多分析师达成一致共识，认为该股票具有潜在的上涨空间。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20241220/20241220133710_67277.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241220/20241220133710_67277.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688235","06160","BGNE"],"gpt_icon":0},{"id":"2492177448","title":"百济神州下跌2.33%，报171.775美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492177448","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492177448?lang=zh_cn&edition=full","pubTime":"2024-12-19 23:30","pubTimestamp":1734622205,"startTime":"0","endTime":"0","summary":"12月19日，百济神州(BGNE)盘中下跌2.33%，截至23:30，报171.775美元/股，成交744.89万美元。财务数据显示，截至2024年09月30日，百济神州收入总额26.82亿美元，同比增长47.03%；归母净利润-4.93亿美元，同比增长4.13%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/19233046611274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4504","BK1161","BGNE","BK4585","BK4535","BK1588","BK1583","BK1500","LU2328871848.SGD","688235","06160","LU0307460666.USD","BK4526","LU0588546209.SGD","BK4505","BK4139","BK4588","BK0239","BK4548","LU1969619763.USD"],"gpt_icon":0},{"id":"2492364198","title":"百济神州12月18日遭南向资金减持79.79万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492364198","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492364198?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:30","pubTimestamp":1734571824,"startTime":"0","endTime":"0","summary":"12月18日，南向资金减持百济神州79.79万股。截止当日收盘，港股通共持有百济神州6988.06万股，占流通股5.02%。百济神州近5个交易日下跌3.24%，港股通累计增持74.91万股；近20个交易日下跌8.83%，港股通累计增持680.86万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093800ab832941&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093800ab832941&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2328871848.SGD","688235","BK1583","BK1588","BGNE","BK1500","06160","LU0588546209.SGD","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2492730972","title":"美股异动｜百济神州盘前续涨0.84% 获多家机构给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492730972","media":"港股那点事","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492730972?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:16","pubTimestamp":1734513360,"startTime":"0","endTime":"0","summary":"格隆汇12月18日｜昨日收涨1.55%的百济神州(BGNE.US)今日美股盘前续涨0.84%，报180.56美元。富瑞集团分析师Kelly Shi维持百济神州买入评级，维持目标价286美元。TD Cowen分析师Yaron Werber维持百济神州买入评级，维持目标价260美元。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-12-18/doc-inczwpwu1005872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","06160","BGNE"],"gpt_icon":0},{"id":"2492784647","title":"百济神州下跌2.02%，报175.725美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492784647","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492784647?lang=zh_cn&edition=full","pubTime":"2024-12-17 04:25","pubTimestamp":1734380733,"startTime":"0","endTime":"0","summary":"12月17日，百济神州(BGNE)盘中下跌2.02%，截至04:25，报175.725美元/股，成交6016.12万美元。财务数据显示，截至2024年09月30日，百济神州收入总额26.82亿美元，同比增长47.03%；归母净利润-4.93亿美元，同比增长4.13%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/17042546450048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK0239","BK4139","BK1161","BK1588","BK1500","BK4548","688235","LU0588546209.SGD","BK4526","BGNE","BK1583","06160","LU2328871848.SGD","BK4505","LU0307460666.USD","BK4504","BK4588","BK4535","LU1969619763.USD","BK4585"],"gpt_icon":0},{"id":"2491866271","title":"A500指数迎首次调仓 纳入寒武纪、百济神州等千亿市值龙头股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491866271","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491866271?lang=zh_cn&edition=full","pubTime":"2024-12-16 19:18","pubTimestamp":1734347889,"startTime":"0","endTime":"0","summary":"中证A500指数收跌0.70%，报4617.17点。22只跟踪中证A500指数的ETF集体收跌，成交金额为286.56亿元，较上一个交易日减少56亿元。换手率方面，工银瑞信A500ETF位居第一，达到68.01%。值得注意的是，近日，中证A500指数迎来首次调仓，更换21只样本，于2024年12月13日收市后正式生效。文章来源：21世纪经济报道视频｜A500指数迎首次调仓，纳入寒武纪、百济神州等千亿市值龙头股","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216195928ab7c4898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216195928ab7c4898&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0588546209.SGD","BK1500","BGNE","BK1588","LU2328871848.SGD","LU1969619763.USD","06160","LU0307460666.USD","BK1583"],"gpt_icon":0},{"id":"2491483686","title":"百济神州12月13日获南向资金加仓74.66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491483686","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491483686?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312623,"startTime":"0","endTime":"0","summary":"12月13日, 南向资金增持百济神州74.66万股。截止当日收盘，港股通共持有百济神州7003.07万股，占流通股5.04%。百济神州近5个交易日下跌12.58%，港股通累计增持152.00万股；近20个交易日下跌4.83%，港股通累计增持862.22万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093317a1f1a88e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093317a1f1a88e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1500","BK1588","LU2328871848.SGD","688235","BK1161","BGNE","LU1969619763.USD","LU0307460666.USD","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2491001555","title":"百济神州(06160)因购股权获行使发行130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491001555","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491001555?lang=zh_cn&edition=full","pubTime":"2024-12-16 08:16","pubTimestamp":1734308210,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，因一名董事于2024年12月14日行使购股权而发行130万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1583","06160","BK1500","BK4505","BK4588","LU2328871848.SGD","BK4548","BK4535","LU1969619763.USD","LU0307460666.USD","BK4585","BK4504","688235","BK4139","BK1588","LU0588546209.SGD","BK1161","BGNE","BK4526"],"gpt_icon":0},{"id":"2491527611","title":"周一重磅！中证A500指数首次调仓“换血”！21进21出，寒武纪、百济神州、赛力斯等千亿龙头重磅加盟！","url":"https://stock-news.laohu8.com/highlight/detail?id=2491527611","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491527611?lang=zh_cn&edition=full","pubTime":"2024-12-15 20:12","pubTimestamp":1734264720,"startTime":"0","endTime":"0","summary":"12月13日，A股放量单边下行，核心资产未能幸免。中证A500指数收跌2.3%止步三连涨，所覆盖的各行各业500只龙头股中仅39股收涨，利亚德20CM涨停，兆易创新10%涨停；下跌方面，移远通信重挫6%居首，爱美客、东方财富、同花顺等十余股跌超5%。　　两市唯一尾号500的中证A500ETF华宝低开低走，场内收跌2.21%报1.02元，大幅回调之后，目前收盘价仍领跑沪市所有A500ETF。首先关注中证A500指数首次调仓。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2024-12-15/doc-inczqazf3599770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688256","BK0012","LU0307460666.USD","LU0588546209.SGD","LU1969619763.USD","BK4548","BK0239","BGNE","159338","BK4504","BK4139","BK4585","BK0185","BK0201","BK1161","BK0014","BK4535","BK1588","BK0264","BK4588","BK1500","BK4505","BK0231","06160","688235","BK1583","BK4526","000510.SH","BK0028","LU2328871848.SGD","601127"],"gpt_icon":0},{"id":"2491741463","title":"石药集团牵手百济神州 AI驱动的临床候选药物BD正在流行","url":"https://stock-news.laohu8.com/highlight/detail?id=2491741463","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491741463?lang=zh_cn&edition=full","pubTime":"2024-12-13 23:40","pubTimestamp":1734104400,"startTime":"0","endTime":"0","summary":"值得注意的是，被跨国药企和国内创新药“一哥”看中的两款药物，均为AI技术驱动获得的临床候选药物。3个月内，石药集团达成2项AI驱动临床候选药物BD根据协议，针对SYH2039的BD交易将为石药集团带来总计1.50亿美元的预付款，最高1.35亿美元的潜在开发里程碑付款，最高15.50亿美元的潜在销售里程碑付款，以及根据产品的年度销售净额计算的分层销售提成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213234245a1ec54b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"2bd1da8968938d1560b07541b5ceaff6","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213234245a1ec54b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4139","BK4535","BK4504","BGNE","BK4588","BK4548","BK4526","BK4505","BK4585"],"gpt_icon":0},{"id":"2491699343","title":"百济神州联手石药达成18亿美元交易，但石药股价下跌4%，为何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2491699343","media":"MedTrend医趋势","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491699343?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:00","pubTimestamp":1734076810,"startTime":"0","endTime":"0","summary":"消息发布后，今日开盘石药集团股价即下跌0.6%，此后一路下行，截至收盘股价下跌超4%。百济神州A股上涨1%。重磅肿瘤产品集采中标，业绩进一步承压2024年前三季度，石药集团营收226.86 亿元，较去年同期下跌4.9%。作为支柱业务的成药业务，前三季度收入186.70 亿元，同比下降3.5%。子公司新诺威营收14.79亿元，同比下降23.66%，归母净利润1.39亿元，同比下降63.50%。预计随着多美素在国采中标降价后，石药集团的营收将进一步受到挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161708ab74c0a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161708ab74c0a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0326950275.SGD","LU2328871848.SGD","BK1583","LU1152091168.USD","BK1521","BK1500","LU1226287529.USD","688235","LU1951186391.HKD","LU1960683339.HKD","IE00BZ08YR35.GBP","SG9999004220.SGD","06160","LU0307460666.USD","LU1226288253.USD","BK1161","IE00BZ08YT58.USD","LU1993786604.SGD","LU1226287792.SGD","LU0067412154.USD","LU1226288170.HKD","LU0588546209.SGD","IE0008368742.USD","IE0008369823.USD","BK1515","LU1226287875.USD","BGNE","LU0140636845.USD","01093","LU0880133367.SGD","BK1191","LU1152091754.HKD","LU1969619763.USD","LU0072913022.USD","IE00B031HY20.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1807302812.USD","IE00B543WZ88.USD","LU0501845795.SGD","BK1588","LU1008478684.HKD"],"gpt_icon":1},{"id":"2491348712","title":"石药集团向百济神州授权AI筛选产品，总金额预计超百亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2491348712","media":"中新经纬","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491348712?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:05","pubTimestamp":1734073540,"startTime":"0","endTime":"0","summary":"以此计算，石药集团本次向百济神州授权总金额将达到18.35亿美元。石药集团本次向百济神州授权的SYH2039，是一款MAT2A抑制剂，是石药集团通过AI驱动的小分子药物设计平台获得的临床候选药物。百济神州在11月13日，三季报披露当晚公告称，将使用部分超募资金4.89亿元用于永久补充流动资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213160711a1eb6351&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213160711a1eb6351&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","BK4139","BK4548","BK4585","BK4526","BGNE","BK4505","BK4535","BK4588"],"gpt_icon":0},{"id":"2491364721","title":"石药集团(01093)与百济神州就SYH2039订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491364721","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491364721?lang=zh_cn&edition=full","pubTime":"2024-12-13 08:30","pubTimestamp":1734049820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，集团已与 BeiGene Switzerland GmbH(百济神州)就集团的新型甲硫氨酸腺苷转移酶2A(MAT2A)抑制剂(SYH2039)，以及后续开发的由该化合物组成或含有该化合物的任何药品在全球的开发、制造及商业化订立独家授权协议。根据该协议并按照其中的条款及条件，集团同意授予百济神州在全球开发、制造及商业化该化合物及该产品的独家授权。集团将收取总计1.50亿美元的预付款，并有权收取最高1.35亿美元的潜在开发里程碑付款及最高15.50亿美元的潜在销售里程碑付款，以及根据该产品的年度销售净额计算的分层销售提成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0072913022.USD","BK0239","01093","BK1583","06160","LU0326950275.SGD","LU1152091168.USD","LU1993786604.SGD","BK1500","BK1191","BK4505","IE00BZ08YS42.EUR","LU1807302812.USD","LU0501845795.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU0140636845.USD","BK4588","LU2328871848.SGD","LU1951186391.HKD","LU1226287792.SGD","IE0008368742.USD","LU1152091754.HKD","BK4548","BK4535","LU1969619763.USD","BK4585","LU0307460666.USD","LU0067412154.USD","BK4504","LU1226287529.USD","688235","BK1521","LU0880133367.SGD","SG9999004220.SGD","BK4139","IE00BZ08YR35.GBP","IE00B543WZ88.USD","BK1515","IE0008369823.USD","BK1588","LU1226288253.USD","LU0588546209.SGD","BK1161","BGNE","LU1960683339.HKD","LU1008478684.HKD","LU1226288170.HKD","IE00BZ08YT58.USD","BK4526"],"gpt_icon":0},{"id":"2491355363","title":"百济神州下跌2.18%，报180.355美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491355363","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491355363?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:59","pubTimestamp":1734029974,"startTime":"0","endTime":"0","summary":"12月13日，百济神州(BGNE)盘中下跌2.18%，截至02:59，报180.355美元/股，成交3444.43万美元。财务数据显示，截至2024年09月30日，百济神州收入总额26.82亿美元，同比增长47.03%；归母净利润-4.93亿美元，同比增长4.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/13025946339872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["688235","BK1500","BK4139","BGNE","LU1969619763.USD","BK4548","BK0239","LU0307460666.USD","BK4535","BK1161","BK1588","LU0588546209.SGD","BK4504","BK4588","BK1583","BK4585","06160","BK4526","LU2328871848.SGD","BK4505"],"gpt_icon":0},{"id":"2490825750","title":"【券商聚焦】野村料中国医药行业明年首季增速可回升 看好百济神州(06160)及药明合联(02268)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825750","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490825750?lang=zh_cn&edition=full","pubTime":"2024-12-12 12:22","pubTimestamp":1733977355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 野村中国医药保健行业研究部主管张佳林指，今年中国医疗市场仍面对困境，等待复苏。展望未来，他指，有不少企业近年致力于拓展海外市场，同时近期以来国家医保局多次公开探讨商业健康险发展，对创新药普及有帮助。张佳林预计，在低基数及潜在需求逐步释放下，明年首季及上半年行业收入增长将重新加快，看好GLP-1新药及抗体偶联药物ADC等前景，又指行业估值处于较低水平，亦为未来的反弹提供基础，在生物科技股中较看好百济神州(06160)，认为其海外市场特别是美国地区销售表现强劲，而在CRO板块则看好药明合联(02268)的高增长潜力及合理估值。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0185","BK0239","BK0010","BK0028","BK4139","02268","BK1161","BK1588","BK1500","BK0250","600056","BK4548","688235","LU0588546209.SGD","BK0082","BK4526","BGNE","BK1583","06160","LU2328871848.SGD","BK4505","BK1141","LU0307460666.USD","BK4504","BK4588","BK4535","SG9999014674.SGD","BK0188","LU1969619763.USD","BK0175","BK4585"],"gpt_icon":0},{"id":"2490864630","title":"百济神州下跌2.05%，报183.665美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490864630","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490864630?lang=zh_cn&edition=full","pubTime":"2024-12-11 23:56","pubTimestamp":1733932619,"startTime":"0","endTime":"0","summary":"12月11日，百济神州(BGNE)盘中下跌2.05%，截至23:56，报183.665美元/股，成交1624.19万美元。财务数据显示，截至2024年09月30日，百济神州收入总额26.82亿美元，同比增长47.03%；归母净利润-4.93亿美元，同比增长4.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/11235646287067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1583","BK4548","BK4139","BK4585","688235","BK4505","BK1161","LU0307460666.USD","BGNE","06160","BK0239","BK4535","LU2328871848.SGD","BK1588","LU0588546209.SGD","LU1969619763.USD","BK4526","BK4504","BK1500","BK4588"],"gpt_icon":0},{"id":"2490756072","title":"百济神州因董事行使购股权而发行54.288万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2490756072","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490756072?lang=zh_cn&edition=full","pubTime":"2024-12-11 09:21","pubTimestamp":1733880060,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）公布，因一名董事于 2024 年 12月10日行使购股权而发行54.288万股股份，每股发行价6.5美元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-11/doc-incyzzcv4160554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","BK1500","BK4139","BGNE","LU1969619763.USD","BK4548","BK0239","LU0307460666.USD","BK4535","BK1161","BK1588","LU0588546209.SGD","BK4504","BK4588","BK1583","BK4585","06160","BK4526","LU2328871848.SGD","BK4505"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.1262},{"period":"6month","weight":0.1306},{"period":"1year","weight":-0.0033},{"period":"ytd","weight":-0.0214}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.01513},{"month":6,"riseRate":0.555556,"avgChangeRate":0.015441},{"month":7,"riseRate":0.777778,"avgChangeRate":0.136456},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.555556,"avgChangeRate":0.060012},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.040753}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}